Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfol...
Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX.
Chief Executive Officer and President Reshma Kewalra
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
On a conference call announcing the deal, Vertex CEO
